



May 21, 2021

Interagency Collaborative to Accelerate Research on Epilepsy (ICARE) *Research Updates*



National Institute of
Neurological Disorders
and Stroke


National Institute of Neurological Disorders and Stroke



*The mission of NINDS is to seek **fundamental knowledge** about the brain and nervous system and to use that knowledge to **reduce the burden** of neurological disease*

Strategies:

- Invest in basic, translational and clinical research
- Identify gaps in research and public health needs
- Train a talented and diverse research workforce
- Support development of tools and resources to enable discoveries
- Communicate and collaborate with all stakeholders, including the public
- Evaluate and continuously improve all NINDS programs




NINDS Appropriation History

(Dollars in Thousands)




	FY 2018	FY 2019	FY 2020	FY 2021 Appropriation	
NINDS Base	1,776,720	1847,660	1,979,476	2,014,208	1.75% increase
BRAIN \$ to NINDS Base	111,410	111,410	128,890	178,890	
21st Century Cures	43,000	57,500	70,000	50,000	
HEAL	213,900	257,843	266,321	270,295	
Total NINDS Appropriation	2,145,030	2,274,413	2,444,687	2,513,393	2.8% increase

NIH and NINDS Funding for Epilepsy Research



Curing the Epilepsies: Setting Research Priorities



Meeting sessions can be viewed on NIH Videocast:

Day 1: <https://videocast.nih.gov/watch=36065>


Day 2: <https://videocast.nih.gov/watch=36066>

Day 3: <https://videocast.nih.gov/watch=36073>

This conference was an opportunity for all epilepsy research stakeholders to provide input on the transformative research priorities for the field, and to come together to find ways to move toward “Curing the Epilepsies”

- 2021 Benchmarks: The revised benchmarks will serve an important need to continue to foster a breadth of research on the epilepsies across all four Benchmark Areas
- Transformative Research Priorities: Several recurring themes were discussed throughout the conference and will continue to be the topics of ongoing discussions
 - Need to foster and support ideas and mechanisms to advance sharing and collaboration, such as a greater use of “center-without-walls” and other team science models

NINDS-sponsored Workshops on the Epilepsies



- Held November 9, 2020
- Meeting presentations can be viewed on the YouTube channel: **NIHNINDS** <https://bit.ly/3kwjXvD>

Post-Traumatic Epilepsy: Models, Common Data Elements, and Optimization

- Sessions are ongoing:
March 18, April 22, May 20, and June 17, 2021
- Meeting website:
<https://event.roseliassociates.com/post-traumatic-epilepsy>



Joint CDC-NINDS Webinar Introduction to Health Services Research in the Epilepsies



**A Joint CDC-NIH Webinar
June 9, 2021
3:30 – 5:00 pm Eastern
Time**

Join ZoomGov Meeting

<https://cdc.zoomgov.com/j/1619474467?pwd=bWloUHRIajhhRzNQMEJuSENhaE14Zz09>



Objectives:

- 1) To increase understanding of HSR objectives and approaches.
- 2) To increase understanding of how HSR can be used to close gaps in health care and management of epilepsy.
- 3) To increase understanding of underutilized resources for conducting epilepsy HSR studies.

NINDS Epilepsy Therapy Screening Program (ETSP)



ETSP provides preclinical screening to identify new treatments for epilepsy



- Recently approved treatments the ETSP contributed to the identification include: XCOPRI (cenobamate) and Epidiolex (cannabidiol)

The ETSP was reviewed in 2020 by a Working Group of the NINDS Advisory Council

- Key Recommendations:
 - Continue focus on identifying treatments for drug resistant epilepsy
 - Enhance capabilities to provide pharmacokinetic data
 - Expand anti-epileptogenesis/disease modification screening capabilities

ETSP Program Director - Brian Klein, PhD

ETSP contract screening site PI- Karen Wilcox, PhD



Epilepsy Centers Without Walls (CWOWs)



The Epilepsy Bioinformatics Study for Antiepileptogenic Therapy ([EpiBiosS4Rx](#)) will use studies of animals and patients with traumatic brain injury (TBI) leading to post-traumatic epilepsy (PTE) in order to develop future clinical trials of epilepsy prevention therapies.



The Channelopathy-Associated Epilepsy Research Center ([CAERC](#)) will combine high-throughput technologies and high-content model systems to investigate the functional consequences of genetic variants in channelopathy-associated epilepsy.



The Epilepsy Multiplatform Variant Prediction ([EpiMVP](#)) Center Without Walls will develop a modular, highly integrated platform approach to accelerate determination of the functional, pharmacological, neuronal network and whole animal consequences of genetic variants among a range of clinical epilepsy types.